0000950103-17-003642.txt : 20170419 0000950103-17-003642.hdr.sgml : 20170419 20170419111004 ACCESSION NUMBER: 0000950103-17-003642 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170419 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20170419 DATE AS OF CHANGE: 20170419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37896 FILM NUMBER: 17769173 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: RG24 8EP BUSINESS PHONE: 441256894000 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: RG24 8EP FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp75239_8k.htm FORM 8-K

     
  
  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549
_________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 

 

Date of Report (Date of earliest event reported): April 19, 2017

 

SHIRE PLC
(Exact name of registrant as specified in its charter)

 

Jersey, Channel Islands 0-29630 98-0601486
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

5 Riverwalk, Citywest Business Campus, Dublin 

24, Republic of Ireland

(Address of principal executive offices)  

 

   
Registrant’s telephone number, including area code:     +353 1 429 7700

 

 

(Former name or former address, if changed since last report)

_________________

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events

 

Shire plc has issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits. The following exhibit is filed herewith:

 

99.1       Press Release dated April 19, 2017

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Shire plc
   
   
  By:  /s/ W R Mordan
    Name: Bill Mordan
    Title: Company Secretary

 

Date: April 19, 2017

 

 

 

EXHIBIT INDEX

 

Exhibit No.

  

Description

   
99.1   Press Release dated April 19, 2017

 

 

 EX-99.1 2 dp75239_ex9901.htm EXHIBIT 99.1

Exhibit 99.1

 

Press Release
www.shire.com		  SL_rgb_lo_blue_pms3005 release.jpg

  

Shire to announce first quarter 2017 results

 

Dublin, Ireland – April 19, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), will announce first quarter 2017 earnings on Tuesday May 2, 2017.

 

Results press release will be issued at: 12:00 BST / 07:00 EDT
Investor conference call time: 14:00 BST / 09:00 EDT

 

Live conference call for investors:

 

Flemming Ornskov, MD, Chief Executive Officer and Jeff Poulton, Chief Financial Officer will host the investor and analyst conference call at 9:00 EDT / 14:00 BST.

 

The details of the conference call are as follows:

 

UK dial in: 0808 237 0030 or 020 3139 4830
US dial in: 1 866 928 7517 or 1 718 873 9077
International Access Numbers: Click here
Password/Conf ID: 74545877#
Live Webcast: Click here

 

Replay:

 

A replay of the presentation will be available for two weeks by phone and by webcast for three months. Replay information can be found on the Investor Relations section of Shire’s website at http://investors.shire.com/.

 

For further information please contact:

 

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874

 

NOTES TO EDITORS

 

About Shire

 

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com

 

 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 

 

 

 

 GRAPHIC 3 image_002.jpg GRAPHIC begin 644 image_002.jpg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